Singular Genomics Systems, Inc. (OMIC)
Singular Genomics Systems, Inc. operates in the Medical - Instruments & Supplies industry of the Healthcare sector, headquartered in La Jolla, CA, US. The stock last traded at $20.01, up 0.00% on the session, giving a market capitalisation of $50.8M. On trailing twelve-month figures it carries a trailing P/E of -0.51, a net margin of -3257.3%. Its beta of 1.83 implies it has historically moved more than the broad market.
Singular Genomics Systems, Inc. is a life science technology firm focused on creating advanced next-generation sequencing and multiomics solutions. The company aims to provide researchers and clinicians with innovative tools to accelerate scientific discovery and medical advancements. Among its core products is the G4 Instrument, a compact next-generation sequencer designed to deliver genetic sequencing results, supported by a selection of complementary consumable kits. Singular Genomics also offers the PX Integrated Solution, a versatile multiomics platform that consolidates single-cell analysis, spatial analysis, genomics, and proteomics into a single, unified instrument. To ensure broad compatibility for the G4, the company maintains strategic partnerships with entities like Agilent Technologies, Dovetail Genomics, Lexogen, New England Biolab, QIAGEN, Roche, Twist Bioscience, and Watchmaker Genomics for the validation of their library preparation kits. Additionally, a collaboration with the Broad Institute of MIT and Harvard enables the G4's integration with the Terra data platform. Established in 2016, Singular Genomics Systems, Inc. is headquartered in La Jolla, California.
Singular Genomics Systems, Inc. is most often compared with the following Healthcare names: